Switch theme
Sign up to access all valuation multiples
Lytix Biopharma AS is a clinical-stage biotech company engaged in developing cancer immunotherapies aimed at activating the patient's immune system to fight cancer. Its products, LTX-401 and LTX-315, are in the pipeline. The company operates in Norway and the USA, majority of revenue is from the USA.
2003
11
LTM Revenue $0.7M
LTM EBITDA -$8.0M
$44.4M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Lytix Biopharma has a last 12-month revenue (LTM) of $0.7M and a last 12-month EBITDA of -$8.0M.
In the most recent fiscal year, Lytix Biopharma achieved revenue of $1.1M and an EBITDA of -$9.1M.
Lytix Biopharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Lytix Biopharma valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $0.7M | XXX | $1.1M | XXX | XXX | XXX |
| Gross Profit | $0.6M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 89% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$8.0M | XXX | -$9.1M | XXX | XXX | XXX |
| EBITDA Margin | -1199% | XXX | -837% | XXX | XXX | XXX |
| EBIT | -$8.1M | XXX | -$9.4M | XXX | XXX | XXX |
| EBIT Margin | -1207% | XXX | -861% | XXX | XXX | XXX |
| Net Profit | -$8.0M | XXX | -$9.2M | XXX | XXX | XXX |
| Net Margin | -1192% | XXX | -847% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Lytix Biopharma's stock price is NOK 8 (or $1).
Lytix Biopharma has current market cap of NOK 569M (or $55.7M), and EV of NOK 454M (or $44.4M).
See Lytix Biopharma trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $44.4M | $55.7M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Lytix Biopharma has market cap of $55.7M and EV of $44.4M.
Lytix Biopharma's trades at 40.8x EV/Revenue multiple, and -4.9x EV/EBITDA.
Equity research analysts estimate Lytix Biopharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Lytix Biopharma has a P/E ratio of -7.3x.
See valuation multiples for Lytix Biopharma and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $55.7M | XXX | $55.7M | XXX | XXX | XXX |
| EV (current) | $44.4M | XXX | $44.4M | XXX | XXX | XXX |
| EV/Revenue | 69.8x | XXX | 40.8x | XXX | XXX | XXX |
| EV/EBITDA | -5.8x | XXX | -4.9x | XXX | XXX | XXX |
| EV/EBIT | -5.8x | XXX | -4.7x | XXX | XXX | XXX |
| EV/Gross Profit | 78.3x | XXX | n/a | XXX | XXX | XXX |
| P/E | -7.3x | XXX | -6.0x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -6.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialLytix Biopharma's last 12 month revenue growth is 474%
Lytix Biopharma's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $1.0M for the same period.
Lytix Biopharma's rule of 40 is -1702% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Lytix Biopharma's rule of X is -13% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Lytix Biopharma and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 474% | XXX | 185% | XXX | XXX | XXX |
| EBITDA Margin | -1199% | XXX | -837% | XXX | XXX | XXX |
| EBITDA Growth | -78% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -1702% | XXX | -363% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -13% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.0M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 652% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 961% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Lytix Biopharma acquired XXX companies to date.
Last acquisition by Lytix Biopharma was XXXXXXXX, XXXXX XXXXX XXXXXX . Lytix Biopharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Lytix Biopharma founded? | Lytix Biopharma was founded in 2003. |
| Where is Lytix Biopharma headquartered? | Lytix Biopharma is headquartered in Norway. |
| How many employees does Lytix Biopharma have? | As of today, Lytix Biopharma has 11 employees. |
| Is Lytix Biopharma publicy listed? | Yes, Lytix Biopharma is a public company listed on OSL. |
| What is the stock symbol of Lytix Biopharma? | Lytix Biopharma trades under LYTIX ticker. |
| When did Lytix Biopharma go public? | Lytix Biopharma went public in 2021. |
| Who are competitors of Lytix Biopharma? | Similar companies to Lytix Biopharma include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Lytix Biopharma? | Lytix Biopharma's current market cap is $55.7M |
| What is the current revenue of Lytix Biopharma? | Lytix Biopharma's last 12 months revenue is $0.7M. |
| What is the current revenue growth of Lytix Biopharma? | Lytix Biopharma revenue growth (NTM/LTM) is 474%. |
| What is the current EV/Revenue multiple of Lytix Biopharma? | Current revenue multiple of Lytix Biopharma is 69.8x. |
| Is Lytix Biopharma profitable? | Yes, Lytix Biopharma is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Lytix Biopharma? | Lytix Biopharma's last 12 months EBITDA is -$8.0M. |
| What is Lytix Biopharma's EBITDA margin? | Lytix Biopharma's last 12 months EBITDA margin is -1199%. |
| What is the current EV/EBITDA multiple of Lytix Biopharma? | Current EBITDA multiple of Lytix Biopharma is -5.8x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
